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RESULTS

MicroRNAs are linked to SNPs associated with abnormal blood lipids
To explore whether miRNAs might be functionally linked to human genetic predispositions to abnormalities in circulating levels of cholesterol and (other) lipids, we carried out a systematic analysis of data from GWASs, involving >188,000 individuals, that associated common SNPs with plasma lipid levels 11 . We annotated these results to determine whether sequences encoding miRNAs might be located in proximity (<100 kb) to SNPs linked to aberrant lipid levels 11 . Our analysis identified 69 miRNAs in the vicinity of SNPs with genome-wide significant (P < 5 × 10 −8 ) association with abnormal levels of total cholesterol (TC), HDL cholesterol (HDL-C), LDL-C, or TAGs (Supplementary Table 1 ). In several cases, these genomic loci harbor a nearby protein-coding gene that probably represents the main contributor to the link between the SNP and aberrant blood lipid levels (for example, fatty acid desaturases 1-3 (FADS1-FADS3) on chromosome 11 are associated with altered levels of all four blood lipid categories, and cholesteryl ester transfer protein (CETP) on chromosome 16 is associated with altered levels of HDL-C) 12, 13 . However, many of the loci do not contain an obvious candidate gene.
We reasoned that miRNAs causally linked with abnormal blood lipids would be predicted to target genes associated with cholesterol and lipid or metabolic homeostasis, and/or with cardiometabolic disorders. We first extracted lists of predicted conserved targets for the 69 miRNAs from the widely used TargetScan 6.2 website 14 . We then analyzed these predicted targets using the DAVID gene ontology (GO) program 15 , filtered for statistically significant links with cardiometabolic disorders such as type 2 diabetes, obesity and atherosclerosis (see Online Methods). From these analyses, the top miRNAs with predicted mRNA targets involved in metabolism and metabolic control, and with significant association with cardiometabolic disorders in GO analysis, were miR-128-1 (near SNPs associated with altered TC and LDL-C levels), miR-148a (TC, LDL-C, and TAGs), and the physically closely linked and sequence-related (sharing seed sequence) miR-130b and miR-301b (TC and HDL-C) TC GWAS miR-128 eQTL 11 with total cholesterol (TC), triglycerides (TG), LDL-C (LDL) and HDL-C (HDL) at the regions harboring miR-128-1 (a), miR-148a (b), and miR-130b and miR-301b (c). Color saturation levels correspond to linkage disequilibrium values (R 2 ) to the top SNP for that particular trait in the 1000 genome EUR panel. Genetic recombination rates, estimated from the 1000 Genomes sequencing project, are plotted in blue. (d,e) Regional association plots for the eQTL analysis (top track) aligned against the Willer et al. 11 joint GWAS analysis (middle track) for total cholesterol (TC) for miR-128-1 (d) and LDL cholesterol for miR-148a (e). Green arrows (bottom track) represent miRNA and protein-coding transcripts as annotated by the GENCODE Project. hsa refers to human (Homo sapiens) miRNA. The data show concordance of SNP peaks and eQTL signals, linking miR-128-1 and miR-148a hepatic expression to SNPs associated with abnormal circulating cholesterol levels.
( Fig. 1a-c and Supplementary Tables 2-4) . Notably, the genomic loci harboring these four miRNAs do not have clear candidate genes that might account for the genetic association of these loci with abnormal blood lipid levels. We therefore focused our follow-up studies on these miRNAs as candidate noncoding RNAs contributing to the blood lipid associations identified in GWASs. miR-128-1 is located in intron 18 of R3HDM1, a gene on human chromosome 2 with unknown function; miR-148a is located in a gene-poor intergenic region of human chromosome 7; and miR130b and miR-301b are found in close proximity in an intergenic region near the UBE2L3 gene on human chromosome 22 ( Fig. 1a-c) . The four miRNAs are highly conserved among vertebrates (data not shown) and all four miRNAs are expressed in a number of human tissues (Supplementary Fig. 1 ). miR-128-1 appears to be extensively co-expressed with its host gene R3HDM1 (suggesting that they share the same primary transcript), and miR-148a is predominantly expressed in liver. Notably, the expression of miR-148a and miR-130b was significantly increased in the liver of high-fat diet (HFD)-fed mice and rhesus macaques, suggesting a potential evolutionarily conserved link to metabolic regulatory function (Supplementary Fig. 2) .
Most of the SNPs in our analysis are located in noncoding intergenic or intronic regions, a number of which exhibit hallmarks of enhancers and open chromatin architecture (for example, DNase I hypersensitivity; Supplementary Table 3 ), suggesting that some of these SNPs may alter regulatory DNA sequence elements controlling miRNA expression. To explore whether SNPs located near the four miRNAs are associated in cis with miRNA expression, we performed miRNA expression quantitative trait locus (miR-QTL) analysis using 424 liver samples from gastric bypass surgery patients (clinical information is available in Online Methods). Our analysis revealed a number of potential cis miR-QTLs ( Fig. 1d,e Table 5) , including ones near the miR-128-1 locus that broadly overlap with the GWAS TC SNP region (Fig. 1d) , and to a lesser extent, the LDL-C SNP region (Supplementary Fig. 3a ). In addition, there appears to be a discrete miR-QTL peak near the CXCR4 gene in this locus that is nearby an apparent enhancer, which has been shown to be bound by multiple immune cell-associated transcription factors (for example, PU.1, EBF, PBX3, IRF4; chromatin immunoprecipitation data are referenced in the University of California, Santa Cruz (UCSC) Genome Browser). We speculate that this signal may represent a contribution from immune and/or inflammatory cell infiltration into the liver in the morbidly obese patient population from which the liver samples were taken ( Fig. 1d and Supplementary Fig. 3) ; however, this hypothesis would need to be further tested. There is also a strong miR-QTL peak near miR-148a that includes two SNPs (rs4722551 and rs4719841) in the promoter region of miR-148a ( Fig. 1e; Supplementary Fig. 3b,c and Supplementary Table 5 ); these two SNPs are associated with TC, TAGs and LDL-C levels (Supplementary Table 3 ). There was no apparent overlap between liver miR-QTLs in the miR-130b and miR301b locus and the SNPs identified by GWAS ( Supplementary Fig. 4 and data not shown), suggesting either that liver is not a relevant tissue for such an association, or that the expression of these miRNAs is not linked with the GWAS SNPs in this cohort of obese individuals. Taken together, the results of this miR-QTL analysis underscore the potential of GWASs to identify genomic variants linking miRNA expression to human phenotypes.
MicroRNA regulation of lipid-related genes and cholesterol and lipoprotein trafficking All four miRNAs are predicted to target key regulators of lipid homeostasis and lipoprotein trafficking, including the LDLR, which is important for hepatic clearance of LDL cholesterol from the circulation 16, 17 , as well as the ATP-binding cassette transporter A1 (ABCA1), which is crucial for HDL biogenesis, cholesterol efflux from peripheral cells such as atherogenic macrophages, and reverse cholesterol transport (RCT) [18] [19] [20] (Supplementary Table 4 ). In accordance with these target predictions, introduction of miR-128-1, miR-148a, miR-130b and miR-301b precursor oligonucleotides into human liver-derived (HepG2 hepatoma) cells decreased LDLR and ABCA1 levels, compared to precursor control-transfected cells. Conversely, transfection of antimiR oligonucleotides increased LDLR and ABCA1 levels compared to mock-treated cells (Fig. 2) . The results of the antimiR experiments show that endogenous miRNAs act to repress LDLR and ABCA1 expression in HepG2 cells. These miRNAs are also predicted to target other essential factors involved in lipid and glucose homeostasis (Supplementary Table 4 ). We confirmed that miR-128-1 regulates expression of the insulin receptor (InsR) and the insulin receptor substrate 1 (IRS1), which acts downstream of the insulin receptor in the insulin signaling pathway 21 , as well as expression of SIRT1, a NAD + -dependent energy sensor and lysine deacetylase 22 ( Fig. 2a) . Notably, of these four miRNAs, three (miR-148a, miR-130b and miR-301b) control expression of salt-inducible kinase 1 (SIK1), a regulator of hepatic lipogenesis that inhibits SREBP-1c activity by direct phosphorylation 23 , as well as expression of several components of the heterotrimeric AMP-activated protein kinase (AMPK; PRKAA1 and PRKAA2), a key energy stress sensor and regulator 24 ( Fig. 2b-d) . Moreover, miR-148a regulates expression of carnitine palmitoyltransferase 1 (CPT1A), a central regulator of mitochondrial fatty acid β-oxidation 25 ( Fig. 2b) , whereas miR-130b controls expression of PPAR gamma coactivator 1 alpha (PGC1-α), a transcriptional coactivator, and insulin induced gene 1 (INSIG1), which controls the activity of SREBPs and HMG-CoA reductase 26 (Fig. 2c) . Altogether, our data suggest that these miRNAs may control multiple metabolic regulatory circuits that act in concert, which could result in cumulative effects on metabolic output. Relative luciferase activity (a.u.) Relative luciferase activity (a.u.)
Relative cholesterol efflux (a.u.)
Pre-301b Anti-301b P C P C P C P C P r e -1 2 8 -1 P r e -1 2 8 -1 P r e -1 4 8 a P r e -1 4 8 a P r e -1 3 0 b P r e -1 3 0 b P r e -3 0 1 b P r e -3 0 1 b f g npg LDL-C uptake by the LDLR in the liver is an essential physiological process regulating circulating levels of LDL-C 16 . This process is of clinical importance because of the prominent role of LDLR-dependent hepatic clearance of circulating LDL-C in preventing atherosclerosis and cardiovascular disease 17 . Indeed, elevated hepatic LDLR expression is a key anti-atherosclerotic effect of statins 27 , and mutations in the LDLR gene can cause familial hypercholesterolemia (FH), a severe disease characterized by high levels of circulating LDL-C and premature death owing to accelerated cardiovascular disease 28 . Because of the physiological and clinical importance of the LDLR in regulating circulating LDL-C, and as LDLR expression has not been previously shown to be under miRNA control, we wished to further verify the functional effects of the four miRNAs on LDLR expression and LDL-C uptake. First, we examined whether miR-128-1, miR-148a, miR-130b, and miR-301b regulate LDLR expression directly through its 3′ untranslated region (UTR), which possesses predicted target sequences for these miRNAs (TargetScan 6.2). The 3′ UTR of the human LDLR gene, when fused to the 3′ end of a firefly luciferase reporter, resulted in decreased luciferase activity in HEK293T cells (Fig. 2e) as compared to cells transfected with an empty vector, indicating the presence of repressive elements within the LDLR 3′ UTR. Transfection of miRNA precursors caused further repression, whereas mutation of the predicted miRNA target sites in the LDLR 3′ UTR abolished the effects of the four miRNAs (Fig. 2f) . Next, we evaluated whether the four miRNAs modulate LDL-C uptake into human hepatoma cells. Indeed, internalization of fluorescently labeled LDL-C (Dil-LDL) into HepG2 cells was strongly decreased upon transfection of miR-128-1, miR-148a, miR-130b, and miR-301b as compared to cells transfected with precursor control. Conversely, transfection of antisense oligonucleotides directed against these miRNAs caused a significant increase in Dil-LDL uptake, as compared to scrambled control antimiR-treated cells (Fig. 2g,h) . Together, these findings demonstrate miRNA repression of the LDLR through its 3′ UTR, with functional effects on LDL-C uptake into liver-derived cells.
ABCA1 is a critical component of the RCT pathway responsible for removing cholesterol from peripheral cells (for example, atherogenic macrophages) and transporting it back to the liver for excretion 18 . In particular, ABCA1 facilitates the production of nascent lipid-poor HDL in the liver and intestines, and it acts in peripheral cells and tissues to pump out cholesterol that can then be ferried by HDL back to the liver. Similarly to the 3′ UTR of LDLR, we found that the 3′ UTR of ABCA1 was directly targeted by miR-128-1, miR-148a, miR-130b, and miR-301b, as revealed by miRNA overexpression and the introduction of point mutations into the miRNA target sites in the ABCA1 3′ UTR in the luciferase fusion assay (Fig. 3) . Previous studies have shown that miRNAs such as miR-33a and miR-33b control ABCA1 levels and cholesterol efflux in liver cells and in macrophages, a cell type with direct relevance to atherosclerosis [5] [6] [7] [8] [9] . We found that all four miRNAs identified in the GWAS analysis were similarly able to modulate expression of ABCA1 in the human HepG2 liver cell line and in the mouse macrophage cell line J774 (Fig. 2a-d and Fig. 3c) , as well as in peritoneal macrophages isolated from C57BL/6 mice, which were treated with an LXR agonist (T090) to further activate expression of Abca1 (Fig. 3e) . Accordingly, miR-128-1, miR-148a, miR-130b, and miR-301b significantly affected the cholesterol efflux capacity of these cells (Fig. 2i,j and  Fig. 3d,f) . Ago2 PAR-CLIP analysis 29 in mouse bone marrow-derived macrophages independently identified all four miRNAs as regulators of two distinct sites in the 3′ UTR of Abca1 mRNA (Fig. 3g) . Taken together, our data indicate that miR-128-1, miR-148a, miR-130b, and miR-301b control expression of both LDLR and ABCA1 in functionally relevant cell types, with effects on cholesterol trafficking. miRNA overexpression in mice inhibits hepatic Ldlr and Abca1 expression and modulates circulating cholesterol-lipoprotein levels On the basis of the miR-QTL data linking SNPs associated with abnormal blood lipid levels to miR-128-1 and miR-148a expression, we chose to study the effects of these miRNAs on circulating blood lipids in vivo. atherosclerosis when fed a Western-type diet 30, 31 . Short-term studies (5 d) with tail vein injection of 20 mg/kg antimiR-128-1, antimiR-148a, or control nonspecific LNA antimiR on days 1 and 3, revealed strongly decreased hepatic miR-128-1 and miR-148a levels, indicating potent on-target effects of both the miR-128-1-and miR-148a-targeting antimiRs (Figs. 5 and 6) . As miR-128-1 exhibits some sequence similarity with the miR-27 family and shares a number of targets with those miRNAs, we verified that antimiR-128-1 LNA did not affect hepatic miR-27 levels (Supplementary Fig. 6a ). In accordance with the in vitro studies and in vivo data in C57BL/6J mice, antisense inhibition of miR-128-1 and miR-148a increased hepatic levels of Ldlr as compared with control LNA-treated mice (Figs. 5b and 6b) . AntimiR-148a treatment also markedly elevated hepatic Abca1 levels at both the mRNA and protein levels (Fig. 5b,c) . Although we did not observe consistent effects of antimiR-128-1 treatment on Abca1 expression across the treated animals in the short-term study (data not shown), we found potent de-repression of other targets such as the insulin signaling components Irs1 and the insulin receptor (Insr), with a concomitant increase in insulin signaling output, as evidenced by elevated phosphorylated Akt (Fig. 6b) . These results suggest that abnormal expression of miR-128-1 might contribute to insulin resistance, a hallmark of the metabolic syndrome 1 , as well as to other effects of insulin dysregulation, such as hepatic steatosis and dyslipidemia. The circulating cholesterol and lipid profile of Apoe −/− mice treated with antimiR-148a revealed an increase of HDL-C levels, as expected from the involvement of ABCA1 in HDL-C generation as compared to controls, but little effect on VLDL-associated TAGs (Fig. 5d,f and Supplementary Fig. 6b) . Interestingly, we also observed a decrease in LDL-C levels after inhibition of miR-148a in Apoe −/− mice (Fig. 5d,e) . In this context, because in mice ApoE function is required for LDL-C clearance via LDLR, the decrease in circulating
We first investigated the effects of miR-128-1 and miR-148a overexpression in C57BL/6J mice fed an HFD (60% calories as fat). Mice were injected in the tail vein with lentivirus expressing pre-miR-128-1 or pre-miR-148a, or were injected with a control virus, and then serum and liver were harvested after two weeks. The miRNA-expressing viruses, which also encoded GFP, were active in liver, as assessed by GFP expression (Fig. 4) . In accordance with the in vitro findings, miR-128-1 and miR-148a overexpression strongly reduced hepatic levels of Abca1 and Ldlr compared with control scrambled pre-miRNA expression, and it also altered the expression of other targets such as Irs1 (miR-128-1) and Cpt1a (miR-148a) (Fig. 4a,d-h and data not shown) . The circulating cholesterol and lipid profile of mice overexpressing miR-148a and miR-128-1 revealed a marked reduction in plasma HDL-C levels compared with controls, as expected from the requirement of Abca1 for HDL formation [18] [19] [20] (Fig. 4b,c) .
To evaluate the consequence of inhibition of endogenous miR-128-1 and miR-148a on LDL clearance, we injected locked nucleic acid (LNA) antisense oligonucleotides (antimiRs) into C57BL/6J mice, followed by retro-orbital injection of fluorescently labeled LDL (Dil-LDL), and assessed clearance of LDL in blood over the subsequent 5 h. AntimiR-128-1-and antimiR-148a-treated mice exhibited increased LDL clearance in comparison with controls (Fig. 4i,j) , in keeping with elevated hepatic Ldlr expression and increased hepatic Dil-LDL levels (Supplementary Fig. 5 ).
Antisense inhibition of miR-128-1 and miR-148a in Apoe −/− mice alters cholesterol and metabolism Next, we investigated the effects of antimiR-128-1 and antimiR-148a treatment in Apoe −/− mice fed a Western-type diet. Apoe −/− mice recapitulate some aspects of the abnormal serum lipid profiles observed in humans with dyslipidemia (for example, high VLDL-C and LDL-C levels and low HDL-C levels), and they exhibit accelerated npg LDL-C levels observed after inhibition of miR-148a must result from LDLR-independent processes. AntimiR-128-1-treated Apoe −/− mice exhibited modestly decreased blood levels of VLDL-C and LDL-C and a shift of HDL-C to a smaller and denser form, presumably nascent HDL-C (Supplementary Fig. 6c ). The miRNA-targeting LNA injections did not cause liver toxicity, as assessed by blood levels of alanine transaminase (ALT) and asparagine transaminase (AST) ( Supplementary  Fig. 6d,e) . Together, these findings show that miR-148a and miR-128-1, which are located in genomic regions harboring SNPs associated with abnormal blood lipid levels, regulate circulating lipoprotein-cholesterol levels in vivo in an experimental model of metabolic disease, probably through multiple mechanisms acting in concert (for example, regulation of cholesterol and lipid transporters, hepatic insulin signaling, and cholesterol and TAG production and clearance).
To further test the ability of miR-128-1 and miR-148a to regulate lipid metabolism, as well as the ability of miR-128-1 to affect glucose homeostasis and insulin sensitivity, we carried out longitudinal studies (16 weeks) using once-weekly subcutaneous injection of antimiR-128-1, antimiR-148a (each 20 mg/kg) or control scrambled LNA oligonucleotide in Apoe −/− mice fed a Western-type diet. Long-term antisense antagonism of miR-148a maintained the strong elevation of HDL-C levels seen in the short-term study, whereas the LDL-C-lowering effect found in the short-term treatment was no longer apparent (Fig. 5g-i) . In antimiR-128-1-treated animals, we found strongly decreased circulating total cholesterol levels (~35%), reflected primarily in a reduction of VLDL-C/LDL-C, as well as a marked decrease in VLDL-associated TAGs (~25%), as compared with control LNA-injected mice (Fig. 6c,d) . Gene expression analysis by DNA microarray profiling and quantitative RT-PCR analysis of livers from antimiR-128-1-treated mice showed that the mRNA levels of many predicted miR-128-1 targets (TargetScan 6.2 mouse), including Ldlr and Abca1, were significantly de-repressed ( Supplementary  Fig. 7a and Supplementary Table 6 ). Pathological examination of the livers, as assessed by H&E and Oil Red O staining, showed significantly (P < 0.05) decreased hepatic steatosis in animals treated with antimiR-128-1 ( Fig. 6e and Supplementary Fig. 7c,d ) as compared to controls. We speculate that this effect on steatosis may in part be due to decreased lipogenesis, as Fasn, a rate-limiting enzyme in fatty acid biosynthesis, was downregulated ( Supplementary  Fig. 7a ). AntimiR-128-1-treated mice also showed significantly improved glucose homeostasis and a modest effect on insulin sensitivity, as revealed by intra-peritoneal glucose tolerance test (IP-GTT) and insulin tolerance test (ITT) (Fig. 6f and Supplementary Fig. 7b) . The potent effect of antimiR-128-1 treatment on circulating cholesterol and TAGs in Apoe −/− mice cannot be explained by changes in hepatic Ldlr and Abca1 levels, but may relate to the decreased VLDL secretion that could accompany improved hepatic insulin sensitivity. Accordingly, we observed a modest but significant decrease in VLDL secretion and lowered circulating apoB-100 levels in Apoe −/− mice treated with antimiR-128-1 ( Fig. 6g and Supplementary Fig. 8 ).
DISCUSSION
Previous GWASs have uncovered associations of genes with various human traits; however, to our knowledge, no systematic analysis has been carried out to evaluate potential associations of regulatory noncoding RNAs, such as miRNAs, with such traits. We leveraged GWAS meta-analysis in >188,000 individuals to identify 69 miRNAs located in genomic regions associated with abnormal blood lipid levels. Our work identifies four miRNAs (miR-128-1, miR-148a, miR130b and miR-301b) that regulate LDL-C uptake and cholesterol 
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Mouse lentivirus and antimiR studies. Lentivirus. Lentiviruses encoding miR-128-1 (miRZip-128-1) and miR-148a (miRZip-148a) precursors, as well as a scrambled control (miRZip-Scramble), were obtained from System Biosciences, Inc. (no. CS970MZ-Z). 12-week-old male C57BL/6J mice were purchased from the Jackson Laboratory, Bar Harbor, ME, and fed an HFD supplemented with 60% kcal from milk fat (D12492, Research Diets) during treatment. Mice were injected in the tail vein with 1 × 10 9 pfu/mouse diluted in 100 µl PBS on day 1, and serum and liver were harvested on day 14.
AntimiRs. LNA antimiRs directed against miR-128-1 (TTCACTGTG), miR148a (TTCTGTAGTGCACTG), and a scrambled control LNA oligonucleotide (TCATACTA) were purchased from Exiqon, Denmark. Experiments were performed using 12-week-old male Apoe-null mice. Mice (no. 002052) were purchased from the Jackson Laboratory, Bar Harbor, ME and fed a Western-type diet supplemented with 45% kcal from milk fat (D12451, Research Diets) for 6 weeks before and during treatment. For the short-term (5 d) studies, miR-128-1 and miR-148a LNA antimiRs (20 mg/kg) or control scrambled LNA oligonucleotide were dissolved in PBS (total volume of 200 µl) and administered through tail vein injections on days 1 and 3 at the same time of day on each day of treatment. Mice were sacrificed 48 h after the last tail vein injection. The longitudinal studies were performed in Apoe-null mice fed with a Western-type diet for 16 weeks, with once-weekly subcutaneous injection of the miR-128-1 or miR-148a LNA antimiRs (20 mg/kg) or control scrambled LNA oligonucleotide. Upon sacrifice, livers were collected and ~1 ml of blood was obtained from each mouse by right ventricular puncture. Blood was centrifuged at 8,000 rpm for 5 min to obtain serum, which was frozen at −80 °C. Total serum cholesterol and triglyceride levels were determined with a Heska Dri-Chem 4000 Chemistry Analyzer (Heska, Loveland, CO) at Massachusetts General Hospital, Center for Comparative Medicine, Diagnostic Laboratory. FPLC analysis of pooled serum was carried out as described 5 . All mouse procedures were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
GWAS analysis.
The GWAS analysis was performed by identifying miRNAs located in proximity (<100 kb) of SNPs (P-value <5 × 10 −8 ) associated with total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), highdensity lipoprotein-cholesterol (HDL-C) and triglyceride (TAG) levels 11 . The list of miRNAs was extracted from miRBase (release 19). The predicted target genes were extracted using the TargetScan (6.2, Human) and gene ontology/ functional annotation was performed with the DAVID software based on two diseases categories: GENETIC_ASSOCIATION_DB_DISEASE (http:// geneticassociationdb.nih.gov/) and OMIM_DISEASE (http://www.ncbi.nlm. nih.gov/omim). To represent the SNP (P-value <10 −4 ) density in proximity of miRNAs shown in Figure 1 , we extracted the list of SNPs associated with TC, LDL-C, HDL-C and TAG levels previously published by the Global Lipids Genetics Consortium 11, 32 . The recombination values shown in Figure 1b-d were obtained as pre-calculated values from the 1000 Genomes consortium and were accessed from (http://mathgen.stats.ox.ac.uk/impute/ALL_1000G_ phase1integrated_feb2012_impute/). The R2 calculations were produced using Plink with the 1000 Genomes phase 1 variants for the EUR (CEU, TSI, FIN, GBR, IBS) populations. miR-QTL analysis using a RYGB patient cohort. For this study, we were interested in finding cis QTLs for four miRNAs: miR-128-1 (chromosome 2), miR148a (chromosome 7), and the physically closely linked and related miR-130b and miR-301b (chromosome 22 -their seed sequences are identical). The full data set including QTL and expression analysis of all miRNAs and SNPs profiled will be published separately.
From February 2000 until April 2007, consent was obtained from 1,018 individuals undergoing Roux-en-Y gastric bypass (RYGB) at the Massachusetts General Hospital to collect and analyze tissue samples removed at the time of surgery. Surgical procedures and the study population have been described previously [33] [34] [35] . Briefly, intraoperative liver samples were collected in RNAlater (Ambion) and stored at −80 °C. Genomic DNA was extracted from liver samples, and 950 samples were successfully genotyped with the Illumina HumanHap 650Y BeadChip array at the Gene Expression Laboratory of Rosetta Inpharmatics.
MicroRNAs were extracted from liver tissues and RT-PCR was performed to derive miRNA expression from the samples using a previously published approach 36 . Standard curves were created for all miRNAs profiled, allowing for the characterization of miRNA abundance as copies/10 pg of total RNA, with a typical mammalian cell containing 10-30 pg of total RNA. All human studies were approved by and conducted in accordance with the ethical standards of the Partners Human Research Committee, and written informed consent was obtained from all participants.
Samples were processed in three separate batches over the course of several years. Because measured miRNA expression may be affected by batch effects as well as by other nongenetic factors, we first determined potential factors that may need to be accounted for in our miR-QTL analysis. For a given factor, we tested for its association with every miRNA using a simple linear regression model. We then compared the resulting association P-value distribution against the uniform distribution; a uniform P-value distribution would be expected if the factor tested does not systematically contribute to the variability of the miRNA expression measurements. This procedure identified that 1) sample processing batch, 2) surgery year, 3) surgery type, and 4) two qPCR controls are significant contributors to the variability of miRNA expression. We therefore corrected for the effects of these factors for all miRNAs using mixed-effect modeling 37 and retained the fitted residuals for miR-QTL analysis. The model we used, expressed using R/lme4 notation, is
where E is the measured expression; here we treat batch, surgery year, and surgery type as random effects and the two control probes (X1 and X2) as fixed effects. Genotyped SNPs were initially filtered to have a minor allele frequency (MAF) >0.01, SNP call rate >95%, individual missing rate <1%, and HardyWeinberg equilibrium (HWE) test P >1e-6. SNPs were then imputed using MaCH-Admix 38 with 1000 Genomes haplotype data (Phase I release version 3) as reference. Imputed SNPs were filtered based on imputation quality (Rsq >0.3). After imputation, the combined genotyped and imputed SNPs were filtered again to ensure MAF >0.03, SNP call rate >95%, individual missing rate <1%, and HWE P >1e-6.
To reduce the potentially confounding effect of race, only Caucasian patients' samples were selected for analysis by excluding the small number of nonCaucasians. Furthermore, to account for population stratification, we computed principal components of SNP genotypes using Eigenstrat 39 and included them in our association model (see below). A total of 424 samples were used to perform miR-QTL analysis.
We performed association between each of the four miRNAs and the SNPs located within 1 Mb on either side of the transcription start site of the miRNAs using a linear, additive model. We included the first 3 principal components of SNP genotypes as covariates in the miR-QTL analysis. Gender, age, and presurgery BMI were also included as covariates. The "Matrix eQTL" package 40 was used to perform the association analysis in R. The "dosage" output (.dose files) from MaCH-Admix was used for association analysis.
Bone marrow-derived macrophage (BMDM) culture and Ago2 PAR-CLIP analysis. Mice were euthanized using carbon dioxide, and bone marrow cells from the femur and tibia were collected by flushing through a 23-gauge needle with PBS. Bone marrow cells were cultured with complete growth media containing DMEM and 20% L929 cell conditioned medium for 6 d (ref. 41) , BMDM for the PAR-CLIP experiment were incubated with 100 µM 4-thiouridine (Sigma) for 16 h, washed with PBS and UV-crosslinked (0.15 J/cm 2 total energy using 365 nm UV light in a Stratalinker (Invitrogen)). BMDM were then harvested and frozen at −80 °C. The details of the PAR-CLIP protocol were described previously 42, 43 with several minor modifications as follows. We used mouse monoclonal anti-mouse AGO2 antibody (Clone 2D4 WAKO) for Ago2 IP. Immunoprecipitated RNA-protein complex was labeled with γ-[ 32 P]-ATP and polynucleotide kinase, purified by PAGE and the cDNA library was prepared for deep sequencing. We used 3′ adapters, 5′ adapters, RT primers, and PCR primers from the Illumina TruSeq Small RNA Sample Preparation Kit. PAR-CLIP npg
